Asepha Secures $4M Seed Funding to Revolutionize Pharmacy Automation with AI

Asepha, a fast-growing startup leveraging AI agents for pharmacy automation, has closed a $4 million Seed round led by Glasswing Ventures and Core Innovation Capital. Other participants included Panache, RedBud, and MGV, with follow-on support from Ripple Ventures and Front Row Ventures.

Founders and Mission

Founded in 2023 by Eunice Wu (CEO) and Can Uncu (CTO), Asepha aims to address critical bottlenecks in pharmacy care using AI. Wu, a Doctor of Pharmacy, brings extensive experience in pharmacy operations, while Uncu has a background in AI engineering, including work on AMD’s MI300X chip, which powers OpenAI and Microsoft Azure.

AI Solutions for Pharmacy Challenges

With 70% of pharmacies understaffed and pharmacists spending up to 90% of their time on administrative tasks, Asepha’s AI tools are designed to streamline operations:

• OCR Prescription Entry Agent: Processes handwritten prescriptions with 96% accuracy, reducing manual data entry.
• Call Agent: Automates 70% of inbound calls, freeing up staff time.
• Browser Navigation Agent: Performs real-time web-based tasks, improving workflow efficiency.

In validation experiments, pharmacists preferred Asepha’s AI responses over human responses 71% of the time in a double-blinded trial.

Funding and Growth Plans

The new funding will support Asepha’s engineering and go-to-market teams, expand global partnerships, and establish a New York City office. The company has already secured multiple Fortune 50 enterprise customers, signaling its early impact in the space.

Leadership Insights

Eunice Wu, CEO and Co-Founder, emphasized the company’s mission: "Asepha allows care teams to focus on what matters most—the people we serve. This funding enables us to scale our vision and bring relief to an overstretched workforce."

Can Uncu, CTO and Co-Founder, highlighted the broader implications: "AI is restructuring industry workflows. We’re building the safety infrastructure for responsible pharmaceutical AI deployment."

Investor Perspectives

Rudina Seseri of Glasswing Ventures praised Asepha’s approach: "By building an agentic API that doesn’t require new interfaces, Asepha circumvents hurdles in regulated industries while enabling frictionless adoption."